Ascendis Pharma A/S
ASND
Helyezés a részvények között
#1500
Ascendis Pharma A/S is a biopharmaceutical enterprise dedicated to advancing... Ascendis Pharma A/S is a biopharmaceutical enterprise dedicated to advancing therapeutic solutions for critical medical conditions that currently lack effective treatments. Its commercialized offering is SKYTROFA, a therapy prescribed for individuals suffering from growth hormone deficiency (GHD). The company boasts a robust development pipeline, featuring several TransCon-branded candidates. These include TransCon Growth Hormone (hGH), which is being progressed for pediatric GHD patients in Japan and for adults with GHD. Also under development are TransCon parathyroid hormone for adults with hypoparathyroidism, and TransCon CNP, aimed at treating pediatric achondroplasia. Further expanding its innovative portfolio, Ascendis is also developing a TransCon toll-like receptor (TLR) 7/8 agonist for intratumoral administration, alongside TransCon IL-2 ß/g, designed for systemic delivery. Founded in 2006, this enterprise maintains its corporate headquarters in Hellerup, Denmark.
Részvényárfolyam
$234.15
Utolsó szinkronizálás: 2026-10-20
Piaci kapitalizáció
$14.61B
Változás (1 nap)
1.82%
Változás (1 év)
16.73%
Ország
DK
Kereskedés Ascendis Pharma A/S (ASND)
Kategória
Healthcare
Ascendis Pharma A/S (ASND) P/S aránya
P/S arány ekkor: October 2026 TTM: 11.93
Ascendis Pharma A/S legfrissebb pénzügyi jelentései és részvényára alapján a vállalat jelenlegi árbevétel aránya (P/S, TTM) 11.93. 2023 végén ez az arány 24.05 volt.
P/S arány története a(z) Ascendis Pharma A/S esetén 2011 és 2026 között
P/S arány az év végén
| Év | P/S arány | Változtassa meg |
|---|---|---|
| 2026 (TTM) | 11.93 | -43.64% |
| 2024 | 21.17 | -11.98% |
| 2023 | 24.05 | -80.76% |
| 2022 | 124.97 | -85.00% |
| 2021 | 833.09 | -16.14% |
| 2020 | 993.40 | 130.30% |
| 2019 | 431.35 | 103.35% |
| 2018 | 212.13 | -70.89% |
| 2017 | 728.64 | 557.34% |
| 2016 | 110.85 | 125.22% |
| 2015 | 49.22 | 161.17% |
| 2014 | 18.84 | 160.08% |
| 2013 | 7.25 | -26.75% |
| 2012 | 9.89 | 0.00% |
| 2011 | 0.00 | 0.00% |
P/S arány hasonló vállalatoknál vagy versenytársaknál
| Vállalat | P/S arány | P/S arány különbség | Ország |
|---|---|---|---|
| 10.02 | -16.00% |
US
|
|
| 40.55 | 239.89% |
US
|
|
| 3.96 | -66.80% |
AU
|
|
| - | - |
CH
|
|
| 10.15 | -14.96% |
NL
|
